238 related articles for article (PubMed ID: 22776426)
21. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.
Obara W; Eto M; Mimata H; Kohri K; Mitsuhata N; Miura I; Shuin T; Miki T; Koie T; Fujimoto H; Minami K; Enomoto Y; Nasu T; Yoshida T; Fuse H; Hara I; Kawaguchi K; Arimura A; Fujioka T
Ann Oncol; 2017 Apr; 28(4):798-803. PubMed ID: 27998971
[TBL] [Abstract][Full Text] [Related]
22. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
[TBL] [Abstract][Full Text] [Related]
23. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
Iwasa S; Yamada Y; Heike Y; Shoji H; Honma Y; Komatsu N; Matsueda S; Yamada A; Morita M; Yamaguchi R; Tanaka N; Kawahara A; Kage M; Shichijo S; Sasada T; Itoh K
Cancer Sci; 2016 May; 107(5):590-600. PubMed ID: 26920496
[TBL] [Abstract][Full Text] [Related]
25. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
[TBL] [Abstract][Full Text] [Related]
26. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW
J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
[TBL] [Abstract][Full Text] [Related]
28. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
29. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer.
Ishikawa H; Imano M; Shiraishi O; Yasuda A; Peng YF; Shinkai M; Yasuda T; Imamoto H; Shiozaki H
Gastric Cancer; 2014 Jan; 17(1):173-80. PubMed ID: 23613128
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients.
Sato Y; Maeda Y; Shomura H; Sasatomi T; Takahashi M; Une Y; Kondo M; Shinohara T; Hida N; Katagiri K; Sato K; Sato M; Yamada A; Yamana H; Harada M; Itoh K; Todo S
Br J Cancer; 2004 Apr; 90(7):1334-42. PubMed ID: 15054451
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
[TBL] [Abstract][Full Text] [Related]
32. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer.
Asahara S; Takeda K; Yamao K; Maguchi H; Yamaue H
J Transl Med; 2013 Nov; 11():291. PubMed ID: 24237633
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
35. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4.
Shingler WH; Chikoti P; Kingsman SM; Harrop R
Int Immunol; 2008 Aug; 20(8):1057-66. PubMed ID: 18567615
[TBL] [Abstract][Full Text] [Related]
36. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
[TBL] [Abstract][Full Text] [Related]
37. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine.
Narita M; Kanda T; Abe T; Uchiyama T; Iwafuchi M; Zheng Z; Liu A; Kaifu T; Kosugi S; Minagawa M; Itoh K; Takahashi M
Int J Oncol; 2015 Apr; 46(4):1699-709. PubMed ID: 25625346
[TBL] [Abstract][Full Text] [Related]
38. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery.
Tanaka S; Harada M; Mine T; Noguchi M; Gohara R; Azuma K; Tamura M; Yamada A; Morinaga A; Nishikori M; Katagiri K; Itoh K; Yamana H; Hashimoto T
J Immunother; 2003; 26(4):357-66. PubMed ID: 12843798
[TBL] [Abstract][Full Text] [Related]
39. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
Mazzaferro V; Coppa J; Carrabba MG; Rivoltini L; Schiavo M; Regalia E; Mariani L; Camerini T; Marchianò A; Andreola S; Camerini R; Corsi M; Lewis JJ; Srivastava PK; Parmiani G
Clin Cancer Res; 2003 Aug; 9(9):3235-45. PubMed ID: 12960108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
